92
Views
6
CrossRef citations to date
0
Altmetric
Original Articles

Loc108167440 suppressed myeloma cell growth by P53-mediated apoptosis

, , , , , , , , & ORCID Icon show all
Pages 2541-2548 | Received 17 Oct 2018, Accepted 26 Feb 2019, Published online: 05 Apr 2019
 

Abstract

Multiple myeloma (MM) results from biased proliferation of cancerous plasma cells (PC). Therapeutic strategies that target MM PC will provide immense value to the treatment of MM. For this, it is necessary to identify novel molecules that differ between MM PC and healthy PC. RNA sequencing was used to determine differences in gene expression profiles between LPS-induced plasmablasts (PB)/PC and the PB-like myeloma SP 2/0 cell line. Compared to LPS-induced PB/PC, SP 2/0 cells expressed significantly lower levels of Loc108167440 mRNA. Loc108167440 overexpression reduced the number of SP 2/0 cells by stimulating apoptotic cell death. In addition, Loc108167440 overexpression suppressed tumor progression in the SP 2/0 xenograft mouse model. Finally, we demonstrated that Loc108167440 overexpression up-regulated expression of p53 in SP 2/0 cells. These results suggest that Loc108167440 overexpression suppressed SP 2/0 cell growth by inducing p53-mediated apoptosis. Thus, Loc108167440 overexpression may be a potential therapy for treating MM.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at http:\\<10.1080/10428194.2019.1590572>

Data availability

The datasets generated and/or analyzed during the current study are available in the ArrayExpress repository, http://www.ebi.ac.uk/arrayexpress/experiments/ E-MTAB-7139.

Additional information

Funding

This work was supported by the National Nature and Science Funds under Grant (31770956 and 81471529), and Beijing Natural Science Foundation under Grant (7182121).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.